Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Historia
24
Películas cinematográficas
16
Música popular
13
Novela estadounidense
12
Jazz
10
Música para órgano
7
Crítica e interpretación
6
Música rock
6
Correspondencia
5
Comedy films
4
Condiciones sociales
4
Diarios íntimos
4
Estados Unidos
4
Música
4
Música vocal (Jazz)
4
Novelistas ingleses
4
Arte
3
Aspectos sociales
3
Bailarines
3
Blues (Música)
3
Christmas music
3
Foreign films
3
Historia y crítica
3
Libros falsos
3
Literatura estadounidense
3
Motetes
3
Música de jazz
3
Operas
3
Songs (High voice) with piano
3
Songs (Medium voice) with piano
3
-
5721por de Haas, Sanne L., Slamon, Dennis J., Martin, Miguel, Press, Michael F., Lewis, Gail D., Lambertini, Chiara, Prat, Aleix, Lopez-Valverde, Vanesa, Boulet, Thomas, Hurvitz, Sara A.“…METHODS: Patients were randomized to receive neoadjuvant T-DM1 + P or TCH + P and assessed for pathologic complete response (pCR; ypT0/is, ypN0). HER2 status (per central assessment), hormone receptor status, PIK3CA mutation status, HER2/HER3 mRNA levels, tumor-infiltrating lymphocyte levels, PD-L1 status, and NanoString data were analyzed. pCR rates by treatment arm were compared across biomarker subgroups. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5722por Shi, Jiyun, Du, Shuaifan, Wang, Rongxi, Gao, Hannan, Luo, Qi, Hou, Guozhu, Zhou, Yidong, Zhu, Zhaohui, Wang, Fan“…BACKGROUND: Due to the temporal and spatial heterogeneity of human epidermal growth factor receptor 2 (HER2) expression in breast tumors, immunohistochemistry (IHC) cannot accurately reflect the HER2 status in real time, which may cause misguided treatment decisions. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5723por Rugo, Hope S., Im, Seock-Ah, Cardoso, Fatima, Cortes, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D., Bachelot, Thomas, Wright, Gail S., Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Schwartz, Gary N., Pluard, Timothy J., Ricci, Francesco, Gwin, William R., Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A., Freedman, Orit, Jakobsen, Erik H., Gal-Yam, Einav Nili, Yerushalmi, Rinat, Fasching, Peter A., Kaufman, Peter A., Ashley, Emily J., Perez-Olle, Raul, Hong, Shengyan, Rosales, Minori Koshiji, Gradishar, William J.Enlace del recurso
Publicado 2023
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5724por Wang, Jiabin, Qiao, Jianghua, Ruan, Yuxia, Wang, Chengzheng, Li, Lianfang, Lu, Zhenduo, Sun, Xianfu, Zhang, Chongjian, Chen, Xiuchun, Yan, Min, Cui, Shude, Liu, Zhenzhen“…BACKGROUND: Human epidermal growth factor receptor-2 (HER-2) protein expression level could serve as a predictor of pathological complete response (pCR) to neoadjuvant trastuzumab-containing regimens. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5725por Paluch-Shimon, Shani, Neven, Patrick, Huober, Jens, Cicin, Irfan, Goetz, Matthew P., Shimizu, Chikako, Huang, Chiun-Sheng, Lueck, Hans Joachim, Beith, Jane, Tokunaga, Eriko, Contreras, Jessica Reyes, de Sant’Ana, Rosane Oliveira, Wei, Ran, Shahir, Ashwin, Nabinger, Sarah C., Forrester, Tammy, Johnston, Stephen R. D., Harbeck, Nadia“…Premenopausal patients with HR+, HER2− tumors may have different tumor biology and treatment response compared to postmenopausal patients. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5726por Li, Zhensheng, Liu, Yunjiang, Li, Yue, Shang, Yuguang, Du, Kaiye, Ji, Xiaohui, Han, Huina, Zhang, Jun“…PURPOSE: To characterize the compliance status of adjuvant endocrine therapy (aET) and its relationship with disease-free survival (DFS) in hormone receptor-positive (HR+) and HER2-negative (HER2−) in Chinese breast cancer (BC) patients with first tumor recurrence. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5727por Chen, Heyan, Maimaitiaili, Amina, Liu, Zhenzhen, Ling, Rui, Zhao, Yi, Yang, Hongjian, Liu, Yunjiang, Liu, Ke, Zhang, Jianguo, Mao, Dahua, Yu, Zhigang, Liu, Yinhua, Fu, Peifen, Wang, Jiandong, Jiang, Hongchuan, Zhao, Zuowei, Tian, Xingsong, Cao, Zhongwei, Wu, Kejin, Song, Ailin, Jin, Feng, He, Jianjun, Fan, Zhimin, Zhang, Huimin“…BACKGROUND: In the era of targeted therapy, whether patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are exempted from anthracycline usage in the neoadjuvant setting is controversial. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5728por Maximilien, Brice“…Her Excellency Ms Sabina Stadler Repnik, Ambassador Extraordinary and Plenipotentiary, Permanent Representative of the Republic of Slovenia to the United NationsOffice and other international organisations in Geneva on Thursday, 19 December 2019.…”
Publicado 2019
Enlace del recurso
-
5729por Tamura, Kenji, Mukohara, Toru, Yonemori, Kan, Kawabata, Yumiko, Nicolas, Xavier, Tanaka, Tomoyuki, Iwata, HirojiEnlace del recurso
Publicado 2023
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5730por Zhang, Baonan, Li, Yuzhen, Zhu, Xiaodan, Chen, Zhe, Huang, Xiaona, Gong, Tingjie, Zheng, Weiwang, Bi, Zhenle, Zhu, Chenyang, Qian, Jingyi, Li, Xiaoqiang, Jin, Chunhui“…BACKGROUND: Chemotherapy is the main treatment strategy for patients with advanced HER2-negative gastric cancer (GC); yet, many patients do not respond well to treatment. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5731por Deng, Ting, Li, Danyang, Yang, Yuchong, Wang, Feixue, Bai, Ming, Liu, Rui, Li, Hongli, Ba, Yi“…BACKGROUND: The KEYNOTE-811 study exhibited promising preliminary results for HER2-positive metastasis gastric adenocarcinoma; however, long-term survival benefit remains to be determined. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5732por Tagliaferri, Barbara, Mollica, Ludovica, Palumbo, Raffella, Leli, Claudia, Malovini, Alberto, Terzaghi, Matteo, Quaquarini, Erica, Teragni, Cristina, Maccarone, Stefano, Premoli, Andrea, Sottotetti, Federico“…In the present real-life study, we investigated the link between clinical complexity and quality of life of patients with HR(+)/HER2(−) ABC treated with CDK4/6 inhibitors. METHODS: We evaluated multimorbidity burden assessed with the Cumulative Illness Rating Scale (CIRS), polypharmacy and patient-reported outcomes (PROs). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5733por Qiao, Fei, Ren, Feng, Lu, Weiting, Yang, Haoran, Mo, Guiling, Wang, Shuangshuang, Liu, Lina, Xu, Xiangtao“…After treatment of UDCA for 29 months, her cirrhosis was improved, hepatic function was close to normal. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5734por Bai, Qianming, Lv, Hong, Bao, Longlong, Yang, Yu, Zhang, Xin, Chang, Heng, Xue, Tian, Ren, Min, Zhu, Xiaoli, Zhou, Xiaoyan, Yang, Wentao“…PURPOSE: To investigate the HER2 status and clinicopathological features in invasive breast cancer with HER2 ≥4.0 and <6.0, which has always been controversial. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5735por Sussell, Jesse A., Press, David J., Hansen, Svenn A., Kim, Eunice, Du Toit, Yolande, Fung, Anita“…RESULTS: Approximately 889,057 women were predicted to be diagnosed with stage I–III HER2-positive BC from 2006 to 2031 in the US and potentially indicated for HER2-targeted treatment. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5736
-
5737por Liu, Yiyuan, Wu, Jinyao, Ji, Zeqi, Chen, Lingzhi, Zou, Juan, Zheng, Jiehua, Lin, Weixun, Cai, Jiehui, Chen, Yaokun, Zheng, Daitian, Chen, Yexi, Li, Zhiyang“…CONCLUSIONS: Abemaciclib plus fulvestrant or ribociclib plus AI appear to be effective and relatively safe for the treatment of HR+/HER2- metastatic or advanced BC patients. However, given the reliance on limited evidence, our findings require further validation through additional studies. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5738por Elnaghi, Khaled Abd Elaziz Ahmed, Alghanmi, Hosam Ali, Elsamany, Shereef Ahmed, Almarzoki, Fathia, Elsafty, Mohamed, Jaffal, Mohammad“…BACKGROUND: CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological factors on survival outcomes with the first-line palbociclib and hormonal therapy. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5739por Kennedy, Laura C., Kazerouni, Anum S., Chau, Bonny, Biswas, Debosmita, Alvarez, Rebeca, Durenberger, Grace, Dintzis, Suzanne M., Stanton, Sasha E., Partridge, Savannah C., Gadi, Vijayakrishna“…Breast MRI features hold promise as biomarkers of early immune response to treatment in HER2+ breast cancer.…”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5740“…Both EGFR exon 20 insertional mutation (Ex20ins) and HER2 Ex20ins demonstrated significant internal heterogeneity in response to dacomitinib, among which specific subtypes (including EGFR D770delinsGY, A763_Y764insFQEA, and HER2 M774delinsWLV) were highly sensitive. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto